

Avoiding obsolescence without instrumentation grants

Strategies for Funding Large Instrument
Upgrades in a Relatively Small Research
Core Facility

Doug Turnbull, GC3F, University of Oregon
WACD Conference, October 2025



GC3F: Genomics and Cell Characterization Core Facility History

- Established in 2008 with HHMI-funded Illumina Genome Analyzer
- Added Flow Cytometry in 2014 (Murdock grant)
- Instrument refresh / expansion in 2016 funded by \$2M Boyle family gift and Murdock Grant (PacBio, 10X, HiSeq 4k)

Chris Doe






GC3F: Genomics and Cell Characterization Core Facility

History




- Even more services added in 2019: Microscopy and Mass Spec
- Illumina Sequencer updated to NovaSeq 6k in 2020 (Murdock grant)
- Became a CLIA lab during the pandemic, \$2M from Oregon Health Authority added lots of capacity

Adam Fries



The joys of running an NGS core...

- PacBio Sequel II Service was "killing it" until mid/late 2023



PacBio Sequencer Refresh effort

- Spoke with leadership about potential Murdock. No dice
- Internal competition for NSF MRI submission. Grrrrrrr....
- Use institutional funds to purchase?
 - Can it "pay for itself"?



Making the case for Revio Purchase (full price)


	A	B	C	D	E	F	G
1	Run Cost	Internal Rate	External rate				
2	\$995	\$1,383	\$2,061				
3							
4	Max cells per week	total percent utilization					
5	20		40%				
6							
7	Actual cells per week	Weekly internal utilization			Weekly External utilization		
8	8		30%			70%	
9							
10	Internal cells per week						
11	2.40						
12	External cells per week						
13	5.60						
14							
15							
16	Gross total weekly revenue						
17	\$14,859						
18							
19	Gross total monthly revenue						
20	\$59,436						
21							
22	Gross total yearly revenue						
23	\$713,230						
24							
25	Net Total weekly revenue			System cost	Weeks to break even		
26	\$6,899			\$779,000		113	
27							
28	Net Total monthly revenue				Months to break even		
29	\$27,596					28	
30							
31	Net Total yearly revenue				Years to break even		
32	\$331,150					2.4	

PacBio rep called with an offer...

- A Revio system used in the All of Us project had been returned and refurbished

All of Us
RESEARCH PROGRAM

	A	B	C	D	E	F	G
1	Run Cost	Internal Rate	External rate				
2	\$995	\$1,383	\$2,061				
3							
4	Max cells per week	total percent utilization					
5	20		40%				
6							
7	Actual cells per week	Weekly internal utilization			Weekly External utilization		
8	8		30%		70%		
9							
10	Internal cells per week						
11	2.40						
12	External cells per week						
13	5.60						
14							
15							
16	Gross total weekly revenue						
17	\$14,859						
18							
19	Gross total monthly revenue						
20	\$59,436						
21							
22	Gross total yearly revenue						
23	\$713,230						
24							
25	Net Total weekly revenue			System cost	Weeks to break even		
26	\$6,899			\$375,000	54		
27							
28	Net Total monthly revenue				Months to break even		
29	\$27,596				14		
30							
31	Net Total yearly revenue				Years to break even		
32	\$331,150				1.1		



Now what do we do about the aging NovaSeq?

- No instrument grants look promising
- Service contract is painfully expensive
- Spoke with First American about lease options
 - Do we really want to own a large sequencer that is over 3 years old?
- Compared cost of NovaSeq X lease to NovaSeq 6k service contract



NovaSeq X lease calculations

	A	B	C	D	E	F	G	
1			Annual			Annual		
2	NovaSeq 6000 annual cost (service contract)		NovaSeq X Lease cost (36 Month)			Added cost for NovaSeq X		
3	\$130,997		\$230,470			\$99,473		
4								
5	Additional Monthly Revenue Needed for X		Monthly NovaSeq X lease payment			Additional monthly cost for X		
6	\$8,289		\$19,206			\$8,289		
7								
8	Average monthly gross Novaseq 6k revenue							
9	\$79,797							
10								
11	Average monthly net Novaseq 6k revenue							
12	\$39,899							
13								
14	Net Revenue needed to “break even” with X							
15	\$48,188							
16								
17	% increase needed to justify lease cost							
18	20.78%							

How many lanes would we need to run with competitive rates?

<u>NovaSeq X</u>				
Run type	Provider	Price	Margin	
10B PE150	<u>genohub california</u>	\$1,500.00	\$360.00	
10B PE150	<u>genohub new jersey</u>	\$2,210.00	\$1,070.00	
10B PE150	<u>SeqCenter</u>	\$1,580.00	\$440.00	
10B PE150	<u>PlasmidSaurus</u>	\$1,500.00	\$360.00	
			Average margin ▶	Monthly lanes needed
			\$557.50	86

Where do we go from here?

- Lean in to expanded Library Prep services
 - Miniaturized WGS preps using Echo and Hamilton liquid handlers: external rate <\$4 per library!
- If you can't beat 'em, join 'em?
 - Outsourcing NovaSeq X lanes to PlasmidSaurus
- Adopt the next generation of sequencing tech early
 - Have been priming leadership for this
 - Maybe Roche?
- Raise rates for services formerly "subsidized" by seq revenue

